1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Global Hospital Care Partnering 2010-2017: Deal trends, players and financials

Global Hospital Care Partnering 2010-2017: Deal trends, players and financials

  • March 2017
  • -
  • Currentpartnering
  • -
  • 900 pages

Summary

Table of Contents

Summary
Global Hospital Care Partnering 2010-2017: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the hospital care partnering deals and agreements entered into by the worlds leading healthcare companies

Description
Global Hospital Care Partnering 2010 to 2017 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Hospital Care partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Hospital Care partnering agreement structure
Hospital Care partnering contract documents
Top Hospital Care deals by value
Most active Hospital Care dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Hospital Care disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hospital Care deals.

The report presents financial deal terms values for Hospital Care deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Hospital Care dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Hospital Care dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Hospital Care deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hospital Care dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Hospital Care deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Hospital Care partnering deals by specific Hospital Care target announced since 2010. The chapter is organized by specific Hospital Care therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Hospital Care partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Hospital Care partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hospital Care technologies and products.

Report scope
Global Hospital Care Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Hospital Care trends and structure of deals entered into by leading companies worldwide.

Global Hospital Care Partnering 2010 to 2017 includes:
- Trends in Hospital Care dealmaking in the biopharma industry since 2010
- Analysis of Hospital Care deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Hospital Care deal contract documents
- Comprehensive access to over 3500 Hospital Care deal records
- The leading Hospital Care deals by value since 2010
- Most active Hospital Care dealmakers since 2010

The report includes deals for the following indications: Accident and emergency, Rehabilitation medicine, Surgery, Orthopedics, Aesthetic procedures, Transplantation, plus other hospital care indications.

In Global Hospital Care Partnering 2010 to 2017, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Hospital care Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,500 hospital care deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Global Hospital Care Partnering 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of Hospital Care deal trends since 2010
- Access Hospital Care deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Hospital Care partner companies
- Comprehensive access to over 750 links to actual Hospital Care deals entered into by the world’s biopharma companies
- Indepth review of Hospital Care deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Hospital Care opportunities
- Uncover companies actively partnering Hospital Care opportunities

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential Summary Immunology is a large therapy area characterized by disorders of ...

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • March 2017
  • by GBI Research

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation Summary Head and neck cancer (HNC) is the sixth most common malignancy worldwide, ...

Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends.  Price & Volume Forecasts by Laboratory Department. 2017 to 2022 -  Global Version

Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Global Version

  • $ 5995
  • Industry report
  • April 2017
  • by Howe Sound Research

“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.